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Introduction
Cancer stem cells (CSCs) in a variety of hematologic malignancies 
and some solid tumors are required for cancer initiation and are 
responsible for disease relapse (1–7). Accumulating evidence sug-
gests that CSCs must be targeted to achieve effective and curative 
therapies for these malignant diseases. A number of genes have 
been shown to regulate CSC proliferation, including Wnt/β-catenin, 
Hedgehog, Notch (3, 4, 8–11), Bim1 (12, 13), p53 (8), p16INK4a (14), 
p19ARF (15), Pten (16), PML (17), PP2A (18), Alox5 (19), TGFB/FOXO 
(20), and Musashi (21). A major challenge is to identify effective tar-
get genes for developing anti-CSC strategies in cancer treatment. 
Because CSCs often express similar markers and are regulated in 
a manner similar to that of their normal stem cell counterparts (22, 
23), it is difficult to develop a therapeutic strategy aimed at selec-
tively targeting CSCs, although Alox5 is specifically required for the 
survival of leukemia stem cells (LSCs) in chronic myeloid leukemia 
(CML) (19). There are some examples showing that although cer-
tain genes play roles in both cancer and normal stem cells, they are 
functionally more critical for cancer than for normal stem cells (24, 
25). In this situation, the difference in the degree of dependence on 
the same genes for survival between cancer and normal stem cells 
provides a therapeutic window for more selective killing of CSCs.
It is reasonable to believe that although the list of aberrantly 
expressed genes in CSCs may be extensive, there exists a selective 
number of genes that play critical roles in regulating the survival 
of CSCs and that could be used as targets for eradicating these 
cells. In this study, taking advantage of our previous identifica-
tion of CML LSCs in mice (26), we used BCR-ABL–induced CML 
as a stem cell disease model to identify effective target genes in 
LSCs, which have been shown to be insensitive to BCR-ABL kinase 
inhibitors in CML mice (27) and in human CML (28, 29). Here, we 
identify Alox15 as a critical regulatory gene for LSC survival. We 
show that Alox15 deficiency or inhibition of  the function of this 
gene causes the depletion of LSCs and prevents the initiation of 
BCR-ABL–induced CML in mice. Alox15 encodes arachidonate 
15-lipoxygenase (15-LO). Compared with Alox5, which we identi-
fied previously (19), Alox15 has similar but also distinct functions 
that are involved in numerous physiological and pathological pro-
cesses, including bone development (30), regulation of inflamma-
tion and immune response (31), and inhibition of proliferation/
survival of malignant cells (32, 33). Thus, it is unlikely that there 
is a complete functional redundancy between Alox5 and Alox15 in 
the maintenance of LSCs.
Results
Alox15 is required for CML induction by BCR-ABL. Because LSCs in 
CML are insensitive to BCR-ABL kinase inhibitors (28) and BCR-
ABL kinase activity is not involved in all signaling pathways acti-
vated by BCR-ABL (26), we hypothesized that there is a group of 
genes whose expression is regulated by BCR-ABL but not restored 
by inhibition of BCR-ABL kinase activity with imatinib. To identify 
these genes in LSCs, we previously conducted a DNA microarray 
study (GEO GSE10912), in which we isolated total RNA from bone 
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Figure 1. Alox15 is essential for CML induction by BCR-ABL. (A) DNA microarray analysis showed upregulation of Alox15 expression by BCR-ABL in 
LSCs compared with GFP+Lin–Sca-1+c-Kit+ cells, which only expressed GFP, and this upregulation was not inhibited by imatinib. Results represent 
the mean ± SD (*P < 0.05). (B) RT-PCR confirmed the upregulation of Alox15 expression by BCR-ABL in LSCs in the presence and absence of imatinib 
treatment (*P < 0.05). Results represent the mean ± SD. (C) Kaplan-Meier survival curves for recipients of BCR-ABL–transduced BM cells from WT or 
Alox15–/– mice (8 mice per group). (D) Left: Gross appearance of CML mice, lung, and spleen of recipients of BCR-ABL–transduced BM cells from WT and 
Alox15–/– donor mice. Right: Photomicrographs of H&E-stained lung and spleen sections from recipients of BCR-ABL–transduced BM cells from WT or 
Alox15–/– donor mice. Original magnification, ×10 (top), ×40 (bottom). (E) In the absence of Alox15, the percentage of GFP+Gr-1+ cells in PB started to 
decrease from day 20 and gradually disappeared after 50 days, whereas the GFP–Gr-1+ cells that did not express BCR-ABL increased. Results represent 
the mean ± SD for each group (n ≥5). (F) Alox15 transgene rescues the defective CML phenotype. BCR-ABL and Alox15 were coexpressed in Alox15–/– BM 
cells by retroviral transduction, followed by transplantation of the transduced cells into recipient mice. Left: BCR-ABL and 15-LO were detected by 
Western blotting using antibodies against ABL and 15-LO in cells transfected with BCR-ABL-IRES-Alox15-pMSCV. Right: Kaplan-Meier survival curves 
for recipients of BCR-ABL-IRES-Alox15-pMSCV–transduced BM cells from Alox15–/– donor mice.
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to cellular compositions in recipient mice after BM transplanta-
tion, we transplanted CD45.1 donor BM cells into lethally irradi-
ated CD45.2 recipient mice. Two weeks later, we analyzed BM 
cells of recipient mice by FACS and found that almost 95% of total 
ungated BM cells (Supplemental Figure 3A) and nearly 100% of 
HSC-containing LSK (Lin–Sca-1+c-Kit+CD45.1) cells (Supplemen-
tal Figure 3B) were donor derived (CD45.1-positive). To examine 
whether BM reconstitution of recipient mice by donor BM cells 
was also true when we induced CML in mice, we transplanted 
BCR-ABL–transduced CD45.1 donor BM cells (GFP+) into lethally 
irradiated CD45.2 recipient mice. On day 14 after transplanta-
tion, we found that almost all BM cells in the leukemic mice were 
also donor derived (Supplemental Figure 2C). To confirm that all 
leukemia cells express GFP in these CML mice, we sorted GFP+ 
or GFP– leukemia cells from the PB of CML mice and assessed 
BCR-ABL transcripts by RT-PCR. We found that BCR-ABL tran-
scripts were only detected in GFP+, but not GFP–, cells (Supple-
mental Figure 3D), indicating that leukemia cells did not lose 
GFP expression in CML mice.
Together, the results described above demonstrate that Alox15 
is essential for induction of CML by BCR-ABL.
Loss of Alox15 causes a functional defect in LSCs. The impaired 
CML development in the absence of Alox15 (Figure 1) could be 
caused by a decrease in the number of LSCs. Therefore, we tested 
whether Alox15 regulates the function of LSCs. We compared the 
numbers of LSCs and normal HSCs (GFP–Lin–Sca-1+c-Kit+) in BM 
of the same CML mice by conducting FACS analyses on days 14 
and 20 after CML induction. At both time points, Alox15 defi-
ciency caused a marked reduction of LSCs as compared with LSCs 
in the BM of WT CML mice (Figure 2A). Loss of Alox15 also caused 
a reduction of normal BM HSCs (GFP–) but did so to a much lesser 
degree compared with GFP+ LSCs (Figure 2A), suggesting that 
Alox15 deficiency has a more profound inhibitory effect on LSCs 
than on normal HSCs. This result was correlated with a more 
profound effect of Alox15 deficiency on BCR-ABL–expressing 
common myeloid progenitors (CMPs), granulocyte-macrophage 
progenitors (GMPs), and megakaryocyte-erythroid progenitors 
(MEPs) than on the corresponding normal progenitor cells (Fig-
ure 2B). Alox15 deficiency did not cause a homing defect in HSCs 
(Supplemental Figure 4), which could cause a delay in CML devel-
opment when the cells were transduced by BCR-ABL.
To test whether loss of Alox15 causes a decrease in the repop-
ulating ability of LSCs, which could lead to a decrease in the 
number of BM LSCs (Figure 2A), we transduced WT (CD45.1) or 
Alox15–/– (CD45.2) BM cells with BCR-ABL to induce CML and 
transplanted equal numbers of WT and Alox15–/– BM cells (1:1 
mixed) from the CML mice into each lethally irradiated second-
ary recipient mouse. On day 14 or 20 after transplantation, more 
than 80% of GFP+Gr-1+ cells in PB of the mice were WT (CD45.1+) 
leukemia cells (Figure 2C), and all these mice eventually died of 
CML (data not shown). These results showed that loss of Alox15 
caused a severe reduction of the repopulating ability of LSCs. Cell 
cycle analysis of LSCs in the BM of CML mice showed that there 
was a higher percentage of LSCs in the S + G2/M phases in mice 
receiving BCR-ABL–transduced Alox15–/– BM cells than in mice 
receiving BCR-ABL–transduced WT BM cells (Figure 2D), pre-
sumably due to the compensatory response of Alox15–/– LSCs to 
marrow (BM) LSCs (GFP+Lin–Sca-1+c-Kit+) in CML mice treated or 
untreated with imatinib and compared gene expression profiles 
between LSCs and normal hematopoietic stem cells (HSCs). The 
study led to our identification of the Alox5 gene (19). In this study, 
we attempted to identify other critical genes in LSCs by starting 
with in-depth analysis of the DNA microarray data. Besides Alox5, 
another gene upregulated by BCR-ABL in LSCs was Alox15, and its 
upregulation was not inhibited by imatinib treatment (Figure 1A). 
The upregulation of Alox15 by BCR-ABL in LSCs with and with-
out imatinib treatment was confirmed by real-time PCR (RT-PCR) 
(Figure 1B). These results imply that Alox15 is involved in the regu-
lation of LSC function by BCR-ABL.
To begin to examine whether Alox15 regulates the function of 
LSCs, we first tested the requirement of Alox15 for CML induction 
by BCR-ABL using Alox15 homozygous knockout (Alox15–/–) mice. 
Mice receiving BCR-ABL–transduced WT BM cells developed and 
died of CML within 4 weeks, whereas mice receiving BCR-ABL–
transduced Alox15–/– BM cells were severely defective in their abil-
ity to induce CML (Figure 1C), which was not related to viral trans-
duction efficiency (Supplemental Figure 1; supplemental material 
available online with this article; doi:10.1172/JCI66129DS1). The 
failure of CML development in the absence of Alox15 correlated 
with a healthier physical appearance of the mice and much less 
infiltration of leukemia cells in the lung and spleen (Figure 1D). 
In addition, FACS analysis of BCR-ABL–expressing (GFP+) mye-
loid (Gr-1+) cells showed that in the absence of Alox15, there was 
a transient growth of leukemia cells in peripheral blood (PB), but 
the number of these cells gradually declined to an undetectable 
level (Figure 1E). In the same animal, we observed a much smaller 
number of leukemia cells (GFP+) than nonleukemia cells (GFP–) 
(Figure 1E), suggesting that Alox15 signaling in maintaining LSC 
survival is much more critical for LSCs than for normal HSCs in 
vivo. To confirm the role of Alox15 in CML development, we con-
ducted a rescue experiment by retrovirally coexpressing BCR-ABL 
and Alox15 in Alox15–/– BM cells to examine whether restoration of 
Alox15 expression reverts the defective CML phenotype caused by 
Alox15 deficiency. We transfected 293T cells and showed that the 
BCR-ABL-IRES-Alox15-pMSCV construct expressed BCR-ABL and 
Alox15 (Figure 1F; left panel). We next showed that compared with 
no CML induction by BCR-ABL in the absence of Alox15, ectopi-
cally expressed Alox15 in Alox15–/– BM cells rescued the defective 
CML phenotype (Figure 1F; right panel); the development of CML 
caused by the ectopic expression of Alox15 with BCR-ABL was con-
sistent with a high percentage of Gr-1+ myeloid cells in PB (Sup-
plemental Figure 2A) and infiltration of leukemia cells in the lung 
and spleen (Supplemental Figure 2B). In contrast, Alox5 did not 
rescue the defective CML phenotype caused by Alox15 deficiency 
(Supplemental Figure 2C), indicating that Alox5 and Alox15 do not 
mutually compensate in function.
We analyzed GFP+ or GFP– cells to reflect the effects of Alox15 
deficiency on growth of leukemia (GFP+) or normal (GFP–) donor 
cells in a recipient mouse (Figures 1 and 2). We used alternative 
approaches to exclude two possibilities after BM transplanta-
tion, namely: (a) could recipient cells contribute significantly to 
the GFP– cell population? and (b) could the GFP– cell population 
contain leukemia cells that had lost their GFP expression for 
unknown reasons? To determine the degree of host contribution 
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from CML mice into secondary recipient mice. We found that in 
the absence of Alox15, BCR-ABL–expressing cells grew at a signifi-
cantly slower rate (Figure 2F) and had severely defective induc-
tion of CML (Figure 2G). Together, these results further indicate 
their reduced stem cell function (Figure 2C). Loss of Alox15 also 
caused increased apoptosis of LSCs but not of normal HSCs (Fig-
ure 2E). To further demonstrate the effect of Alox15 deficiency on 
LSC function, we induced CML and then transplanted BM cells 
Figure 2. Loss of Alox15 impairs LSC function. (A) FACS analysis showed that loss of Alox15 caused a significant reduction of LSCs in the BM of CML 
mice (P < 0.05) and a smaller reduction of normal HSCs (GFP–Lin–c-Kit+Sca-1+) at days 14 and 20 after CML induction. Results represent the mean ± SD. 
(B) Loss of Alox15 caused a more significant reduction of BCR-ABL–expressing (GFP+) (left panel) than of non-BCR-ABL–expressing (GFP–) (right panel) 
CMP, GMP, and MEP cells in the BM of CML mice (n = 4). Results represent the mean ± SD. (C) WT (CD45.1) and Alox15–/– (CD45.2) BM cells from CML mice 
were 1:1 mixed and transplanted into lethally irradiated secondary recipient mice. At days 14 and 20, the percentage of CD45.1+ cells was much higher 
than that of CD45.2+ cells. Results represent the mean ± SD. (D) Cell cycle analysis showed a higher percentage of LSCs in the S + G2/M phase in BM 
cells of Alox15–/– versus WT CML mice. BM cells were stained with Hoechst blue for FACS analysis. The mean percentage for each cell population (n = 5) 
is shown. (E) Alox15 deficiency caused increased apoptosis of LSCs over normal HSCs by staining the cells with 7AAD and annexin V. Results represent 
the mean ± SD. (F and G) Alox15 deficiency impaired the function of BCR-ABL–expressing BM cells in secondary recipient mice receiving 2 × 106 BCR-
ABL–transduced WT (n = 3) or Alox15–/– (n = 4) BM cells per mouse. Alox15 deficiency significantly inhibited BCR-ABL–expressing blood cells (GFP+) (F) and 
prevented CML development (G). Results represent the mean ± SD (**P < 0.01).
Downloaded from http://www.jci.org on May  1, 2016.   http://dx.doi.org/10.1172/JCI66129
The Journal of Clinical Investigation   R e s e a R c h  a R t i c l e
3 8 5 1jci.org   Volume 124   Number 9   September 2014
presence of different concentrations of PD146176 under stem cell 
culture conditions (34). We observed that PD146176 significantly 
suppressed LSCs (GFP+LSK) and CMPs (GFP+Lin–Sca-1–c-Kit+) in 
vitro (Figure 3A). To examine whether PD146176 suppresses LSCs 
in vivo, the CML mice were treated with a placebo or PD146176, 
and the percentages of BM LSCs from the treated CML mice 
were compared between the 2 treatment groups. We found that 
PD146176 inhibited the proliferation of LSCs (Figure 3B) and 
that Alox15 deficiency has a much more profound inhibitory effect 
on LSCs than on normal HSCs.
Inhibition of 15-LO impairs LSC function and attenuates CML 
in mice. Deletion of Alox15 caused an impairment of LSC function 
in CML mice (Figure 2), suggesting that Alox15 is a target gene in 
LSCs. Therefore, we examined whether inhibition of Alox15 func-
tion by the 15-LO inhibitor PD146176 also impairs LSC function. 
We isolated BM cells from CML mice and cultured the cells in the 
Figure 3. Inhibition of Alox15 impairs LSCs and prolongs survival of CML mice. (A) PD146176 inhibited LSCs in vitro. BM cells from CML mice were cul-
tured (2 × 106 cells per well in a 6-well plate) under stem cell conditions in the presence of DMSO or PD146176 for 3 days, followed by FACS analysis of LSCs 
and CMPs (GFP+Lin–Sca-1–c-Kit+). Results represent the mean ± SD. (B) PD146176 inhibited LSC survival in CML mice. CML mice were treated with placebo 
or PD146176, and at day 14 after CML induction, the percentages of BM LSCs in the treated CML mice were compared. A no-treatment control was used for 
FACS analysis. (C) PD146176 induced apoptosis of LSCs in CML mice. On day 14 after CML induction, BM cells from placebo- or PD146176-treated CML mice 
were stained with 7AAD and annexin V, and the percentage of double-positve LSCs was determined by FACS. Results represent the mean ± SD.  
(D) Kaplan-Meier survival curves for CML mice treated with placebo or with PD146176 alone. Inhibition of Alox15 by PD146176 significantly prolonged 
survival of the CML mice (n = 4 for each group). (E) In PD146176-treated CML mice, the effectiveness of PD146176 in treating CML mice correlated with a 
decreased percentage of GFP+Gr-1+ leukemia cells in PB. FACS analysis showed the disappearance of GFP+Gr-1+ cells in the PB of CML mice treated with 
PD146176. Results represent the mean ± SD. (F) Photomicrographs of H&E-stained lung and spleen sections from CML mice treated with placebo or 
PD146176. Scale bars: 100 μM (top); 50 μM (bottom). *P < 0.05; **P < 0.01.
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also induced apoptosis of LSCs (Figure 3C). Next, we examined 
whether 15-LO serves as a potential LSC target for the treatment of 
CML. We found that PD146176 treatment reduced the plasma lev-
els of 15S-hydroxyeicosatetraenoic acid (15S-HETE), a metabolic 
product of 15-LO, in CML mice (Supplemental Figure 5A), indi-
cating that the metabolic function of Alox15 was inhibited in CML 
mice by PD146176. All placebo-treated mice died of CML within 
4 weeks after CML induction, whereas almost all PD146176-
treated CML mice survived (Figure 3D). The effectiveness of 
PD146176 in treating CML mice correlated with a decreased per-
centage of GFP+Gr-1+ leukemia cells in PB (Figure 3E) and a much 
lower degree of leukemia cell infiltration into the lung and spleen 
(Figure 3F). These drug effects were mostly related to inhibition 
of Alox15 function, because PD146176 treatment of mice receiv-
ing BCR-ABL–transduced Alox15–/– BM cells did not significantly 
reduce the percentage of BCR-ABL–expressing cells in the BM of 
the treated mice (Supplemental Figure 5B). In some treated CML 
mice, GFP+Gr-1+ leukemia cells in both the PB and BM dropped 
to an undetectable level after long-term treatment (Supplemental 
Figure 5C). To evaluate the impact of PD146176 on normal HSCs 
in CML mice, we treated CML mice with PD146176 for 90 days. 
BM cells from PD146176-treated CML mice were analyzed by 
FACS on day 90 after CML induction. We found that the number 
of GFP+LSK cells was reduced to 0.016% upon PD146176 treat-
ment, whereas GFP–LSK cell numbers were 10 times higher than 
those of GFP+LSK cells in the treated CML mice, suggesting that 
targeting of Alox15 has a much less inhibitory effect on HSCs than 
on LSCs (Supplemental Figure 5D).
Furthermore, we performed a colony formation assay to test the 
effect of PD146176 on leukemic progenitor cells. PD146176 treat-
ment significantly reduced colony formation both in vitro (Figure 
4A) and in vivo (Figure 4B). Consistently, we observed that loss of 
Alox15 also significantly reduced the colony formation of leukemic 
progenitor cells (Figure 4C). We also conducted a secondary trans-
plantation assay to further examine the effect of PD146176 on 
LSC function. We transplanted BM cells from PD146176-treated 
Figure 4. Inhibitory effect of PD146176 on LSCs. (A and B) Quantitation of colony-forming cells (CFCs) was performed after treating CML cells with 
PD146176 in vitro (A) and in vivo (B). Results represent the mean ± SEM. For the in vitro assay, BM cells from CML mice on day 14 after CML induction 
were treated with PD146176 for 48 or 72 hours and plated into stem cell methocult media. Colonies were counted after 7 days. For the in vivo assay, CML 
mice were treated with PD146176 for 7 days beginning on day 8 after CML induction. BM cells from CML mice were plated, and colonies were counted  
7 days later. (C) The colony-forming ability of Alox15–/– CML BM cells was dramatically decreased compared with that of WT cells. Results represent the 
mean ± SEM. (D) PD146176 caused a significant reduction of leukemia cells in the PB of secondary recipient mice. Results represent the mean ± SD. 
(E) CML mice were treated with placebo (n = 3) or PD146176 (n = 6) beginning on day 8 after CML induction, and after a 7-day treatment, BM cells were 
injected into secondary recipient mice. (F) PD146176 had a weak inhibitory effect on normal HSCs in vivo. CML mice were treated with placebo (n = 4) or 
PD146176 (n = 4). The percentage of HSCs in BM was determined by FACS after a 7-day treatment. Results represent the mean ± SD. (G) CML mice were 
treated with placebo, PD146176, imatinib, or PD146176 and imatinib (PD + IM) for 7 days, and the percentage of PB leukemia cells or BM LSCs was com-
pared. Results represent the mean ± SD. *P < 0.05;**P < 0.01.
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primary CML mice into secondary recipient mice and found that 
inhibition of Alox15 caused a significant reduction of leukemia 
cells in PB (Figure 4D) and delayed CML development in sec-
ondary recipient mice (Figure 4E). By contrast, PD146176 had a 
much weaker effect on normal HSCs (Figure 4F). Next, we tested 
whether PD146176 affects the homing of CML cells, which could 
affect treatment efficacy, and found no significant effect (Supple-
mental Figure 6). Because the BCR-ABL kinase inhibitor imatinib 
is the standard first-line therapy for CML patients, we tested the 
combinatorial effect of PD146176 and imatinib on LSCs in CML 
mice. Compared with imatinib alone, PD146176 alone or in com-
bination with imatinib significantly reduced the percentage and 
total number of LSCs in both BM and PB (Figure 4G). We found 
that addition of imatinib did not further increase the inhibitory 
effect of PD146176, presumably because PD146186 is much more 
effective than imatinib at inhibiting LSCs. Together, these results 
indicate that inhibition of Alox15 function provides a novel thera-
peutic strategy for suppressing LSCs in CML treatment.
Effect of Alox15 deficiency on normal HSCs. Alox15 deficiency or 
inhibition of 15-LO by PD146176 severely impaired the function of 
LSCs in CML mice (Figures 2 and 3), with a much weaker inhibi-
tory effect on normal HSCs in vitro and in CML mice (Figure 2, A 
and E). Here, we more directly examined the effect of Alox15 defi-
ciency on normal HSCs by comparing the percentages and func-
tion of HSCs in WT and Alox15–/– mice. A recent study showed that 
HSC function requires Alox15 (35). We fully characterized hemato-
poietic cell lineages in the BM and PB of Alox15–/– mice in compar-
ison with those of WT mice. The percentages of total HSCs (Lin– 
Sca-1+c-Kit+), long-term HSCs (LT-HSCs) (Lin–Sca-1+c-Kit+CD34–), 
short-term HSCs (ST-HSCs) (Lin–Sca-1+c-Kit+CD34+Flt3–), and 
multipotent progenitors (MPPs) (Lin–Sca-1+c-Kit+CD34+Flt3+) 
in the BM of Alox15–/– and WT mice were similar (Figure 5A, left 
panel), but the total number of these cells was reduced in Alox15–/– 
mice (Figure 5A, right panel). The reduction of the numbers of 
HSCs in the absence of Alox15 suggests that Alox15 contributes to 
HSC self-renewal. However, the percentages of BM CMPs, GMPs, 
and MEPs in Alox15–/– mice were not reduced and were signifi-
cantly higher than those in WT mice (Figure 5B), consistent with 
higher percentages of Gr-1+ and Mac-1+ myeloid cells in the PB 
of Alox15–/– mice (Figure 5C), although the percentage of B lym-
phoid cells (B220+) was significantly lower in the PB of Alox15–/– 
mice (Figure 5C). Furthermore, there were more HSCs in the 
S + G2/M phase of the cell cycle in Alox15–/– mice than in WT mice 
(Figure 5D), indicating that there were more proliferating HSCs in 
Alox15–/– mice, although the numbers of HSCs were significantly 
lower in these mice (Figure 5A, right panel). This result suggests 
that the higher cycling property of Alox15–/– HSCs is a compensa-
tory response to the reduced number of HSCs in Alox15–/– mice, 
which likely explains the higher percentages of myeloid progen-
itor and mature myeloid cells in the BM and PB of Alox15–/– mice 
Figure 5. Effect of Alox15 deficiency on the function of normal HSCs in vitro. (A) Alox15 was required for self-renewal of HSCs. BM cells from WT and 
Alox15–/– mice were analyzed by FACS to determine the percentage (left) and total number (right) of total HSCs (Lin–Sca-1+c-Kit+), LT-HSCs (Lin–Sca-1+ 
c-Kit+CD34–), ST-HSCs (Lin–Sca-1+c-Kit+CD34+Flt3–), and MPPs (Lin–Sca-1+c-Kit+CD34+Flt3+). Results represent the mean ± SD. (B) BM cells from WT and 
Alox15–/– mice were analyzed by FACS to determine the percentage of CMPs, GMPs, and MEPs. Results represent the mean ± SD. (C) Cells from the PB of 
WT and Alox15–/– mice were analyzed by FACS to determine the percentage of Gr-1+, Mac-1+, B220+, and CD3E+ cells. Results represent the mean ± SD.  
(D) Cell cycle analysis showed a higher percentage of HSCs in the S + G2/M phase of the cell cycle in Alox15–/– mice than in WT mice. BM cells were isolated 
from WT or Alox15–/– mice. Cells were stained with Hoechst blue, and DNA content, represented by the percentage of HSCs in the S + G2/M phase of the 
cell cycle, were examined by FACS. Mean percentage for each cell population (n = 3) is shown. Results represent the mean ± SD. (E) Competitive reconstitu-
tion analysis was performed to compare the function of HSCs between Alox15–/– and WT mice. Alox15–/– (CD45.2) and WT (CD45.1) BM cells were 1:1 mixed 
and transferred into recipient mice by tail injection or bone injection (n = 5). Twelve weeks after BMT, FACS analysis showed the percentage of WT and 
Alox15–/– cells in the BM of recipient mice. Results represent the mean ± SD. **P < 0.01.
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ated through the molecular pathway related to the failure of BCR-
ABL–expressing Alox15–/– HSCs to induce CML (Figure 1). The 
DNA microarray analysis showed that in the absence of Alox15, 
the Selp gene,  among others, was upregulated (Figure 7A). We 
have previously shown that Selp, a cell surface adhesion molecule, 
plays a suppressive role in CML development (36, 37), providing a 
rationale for studying the functional relationship between Alox15 
and Selp in CML. We treated K562 cells with PD146176, and FACS 
analysis showed upregulated Selp expression on the cell surface 
(Figure 7B), suggesting that Alox15 suppresses SELP expression. 
This idea was supported by our finding that treatment of the cells 
with 15s-HETE and lipoxin A4, the metabolic products of the 
Alox15 pathway, inhibited the expression of SELP on K562 cells 
(Figure 7C). These results suggest that Selp is a downstream tar-
get gene of Alox15 and mediates the inhibition of LSC function 
by Alox15 deficiency (Figure 2A). To definitively show the regula-
tion of Selp by Alox15, we crossed Alox15–/– mice with Selp–/– mice 
to generate Alox15–/– Selp–/– homozygous double-knockout mice. 
If Selp played a critical role in suppressing the function of LSCs 
in the absence of Alox15, we would expect to see a rescue of the 
defective CML development caused by Alox15 deficiency. Indeed, 
Alox15–/– Selp–/– BM cells transduced with BCR-ABL efficiently 
induced CML in recipient mice (Figure 7D), whereas Alox15–/– BM 
cells transduced with BCR-ABL failed to do so (Figure 1C and 
Figure 7D). As compared with the nonrescue control group, the 
rescue of the defective CML phenotype by the deletion of Selp 
in Alox15–/– BM cells correlated with a higher number of LSCs 
in BM (Figure 7E) (P < 0.05), a higher number of leukemia cells 
(GFP+Gr-1+) in PB (Figure 7F) (P < 0.01), and severe infiltration 
of myeloid leukemia cells into the lung and spleen (Figure 7G). 
A colony-forming assay also showed that Selp deficiency largely 
rescued the defective CML phenotype by the deletion of Selp in 
Alox15–/– BM cells (Figure 8A). This result was consistent with the 
significant reduction of Alox15–/– BM cell apoptosis (Figure 8B). To 
confirm whether Selp has an effect on normal HSCs, we generated 
the MSCV-Selp-GFP construct and used MSCV-GFP as a control 
(Supplemental Figure 7). We transduced BM cells with MSCV-
Selp-GFP or MSCV-GFP retrovirus and found that the percent-
ages of GFP+ cells in PB (Figure 8C) and Lin–Sca-1+c-Kit+ cells in 
(Figure 5, B and C). If this assumption were correct, Alox15–/– HSCs 
would have a lower stem cell function. To test this idea, we com-
pared the function of HSCs in Alox15–/– and WT mice by conduct-
ing a competitive repopulation analysis (Figure 5E) and a BM cell 
engraftment assay (Figure 6A). In the competitive repopulation 
analysis, equal numbers of WT (CD45.1) and Alox15–/– (CD45.2) 
total BM cells were mixed and injected into the same animal intra-
venously or directly into the bone. Twelve weeks after the injec-
tion, we found that the percentage of CD45.2 cells in the PB was 
significantly lower than that of CD45.1 cells (Figure 5E), showing a 
reduced repopulating ability of Alox15–/– BM cells in recipient mice. 
In the BM cell engraftment assay, several doses of Alox15–/– or WT 
BM cells were transplanted into lethally irradiated WT mice. The 
engraftment ability of Alox15–/– BM cells was significantly lower 
than that of WT BM cells, as 1 × 104 or more WT BM cells effi-
ciently protected lethally irradiated recipient mice from death, 
whereas the high numbers of Alox15–/– BM cells only partially res-
cued the irradiated mice (Figure 6A). We also performed a long-
term repopulation assay by transducing BM cells with MSCV-GFP 
to label the donor cells and found that the percentage and total 
number of HSCs (GFP+Lin–Sca-1+c-Kit+) in Alox15–/– transplants 
were significantly lower than in WT controls 4 months after trans-
plantation (Figure 6, B and C). These results indicate that Alox15–/– 
HSCs have some degree of functional defects. However, the effect 
of Alox15 deficiency on normal HSCs is much less than that on 
LSCs, as BCR-ABL–expressing Alox15–/– LSCs completely lost their 
ability to induce CML (Figure 1), indicating a therapeutic window 
for targeting Alox15 in CML treatment.
P-selectin (Selp) is a key mediator for the abolishment of CML 
caused by Alox15 deficiency. To understand the underlying mech-
anism by which BCR-ABL–expressing Alox15–/– BM cells fail to 
induce CML (Figure 1), we compared gene expression profiles 
between WT and Alox15–/– HSCs by performing DNA microarray 
analyses. We intentionally did not compare BCR-ABL–expressing 
WT and Alox15–/– HSCs, because BCR-ABL–expressing Alox15–/– 
HSCs have a profound survival defect in vivo (Figure 2A), which 
makes it difficult to obtain a sufficient number of cells for the anal-
ysis. On the other hand, Alox15–/– HSCs had a functional defect in 
rescuing lethally irradiated mice (Figure 6B), which may be medi-
Figure 6. Effect of Alox15 deficiency on the function of normal HSCs in vivo. (A) A BM cell engraftment assay was performed to compare the function 
of HSCs in Alox15–/– and WT mice. Four doses (1 × 105, 5 × 104, 2.5 × 104, and 1 × 104) of WT or Alox15–/– BM cells were injected into lethally irradiated recip-
ient mice. Survival curves showed that there was defective BM engraftment in the Alox15–/– mice. (B and C) Alox15–/– donor cells exhibited diminished 
long-term repopulation over controls. Alox15–/– and WT BM cells were transduced with an empty GFP–expressing retrovirus, followed by transplantation 
into recipient mice. The percentage (B) and total number (C) of GFP+Lin–c-Kit+Sca-1+ cells were determined 4 months after transplantation. Results 
represent the mean ± SD. **P < 0.01.
Downloaded from http://www.jci.org on May  1, 2016.   http://dx.doi.org/10.1172/JCI66129
The Journal of Clinical Investigation   R e s e a R c h  a R t i c l e
3 8 5 5jci.org   Volume 124   Number 9   September 2014
(Figure 8E), suggesting that Selp regulates HSC function through 
altering the movement and survival of HSCs.
Inhibition of Alox15 function suppresses human CML cells. To 
investigate whether Alox15 is a potential target gene in human 
CML cells, we treated K562 cells with PD146176 in culture for 
48 or 96 hours, respectively, and found that the total cell num-
bers were greatly reduced (Figure 9A). We also tested the effect 
of PD146176 on the non–BCR-ABL–expressing leukemia cell line 
BM (Figure 8D) were much lower in MSCV-Selp-GFP–transduced 
cells than in GFP-transduced cells at day 120 after transplanta-
tion. These results indicate that SELP inhibits HSC function. To 
understand the underlying mechanism by which SELP regulates 
the function of HSCs, we compared gene expression profiles in 
WT and Selp–/– HSCs by conducting DNA microarray analysis. We 
found that loss of Selp led to upregulation and downregulation 
of a group of genes associated with cell adhesion and apoptosis 
Figure 7. Loss of Alox15 depletes LSCs through its downstream gene Selp. (A) Gene expression profiles of WT and Alox15–/– HSCs were compared by 
DNA microarray analysis. In the absence of Alox15, the Selp gene was upregulated. (B) FACS analysis showed that Selp expression on the cell surface was 
upregulated by treating K562 cells with PD146176. (C) FACS analysis showed that Selp expression on K562 cells was downregulated after treatment with 
15S-HETE or lipoxinA4 for 48 hours. (D) Rescue of the defective CML phenotype by the deletion of Selp in Alox15–/– BM cells. Alox15–/– mice were crossed 
with Selp–/– mice to generate Alox15–/–Selp–/– homozygous double-knockout mice. Kaplan-Meier survival curves for recipients of BCR-ABL–transduced BM 
cells from WT, Selp–/–, Alox15–/–, and Selp–/– Alox15–/– donor mice. (E) Rescue of the defective CML phenotype by the deletion of Selp in Alox15–/– BM cells 
correlated with a high number of LSCs in BM. On day 14 after CML induction, LSCs in recipients of BCR-ABL–transduced BM cells from WT, Selp–/–, Alox15–/–, 
and Selp–/– Alox15–/– donor mice were determined by FACS. Results represent the mean ± SD. (F) Rescue of the defective CML phenotype by deletion of Selp 
in Alox15–/– BM cells correlated with a high number of leukemia cells (GFP+Gr-1+) in the PB of recipients of BCR-ABL–transduced BM cells from WT, Selp–/–, 
Alox15–/–, and Selp–/– Alox15–/– donor mice. Results represent the mean ± SD. (G) Photomicrographs of H&E-stained lung sections from recipients of BCR-
ABL–transduced BM cells from WT, Selp–/–, Alox15–/–, and Selp–/– Alox15–/– donor mice. *P < 0.05; **P < 0.01.
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CD34+ cells (greater than 95% of the cells were FISH-positive for 
BCR-ABL translocation) were treated in culture with PD146176 
alone or in combination with imatinib or nilotinib, followed by 
analyses of survival, apoptosis, and colony formation of the cells. 
PD146176 markedly reduced survival (Figure 10A, top panel) and 
induced apoptosis (Figure 10A, bottom panel) of CML CD34+ 
cells. PD146176 in combination with imatinib or nilotinib showed 
a slightly augmented effect as compared with that of single agents 
in the induction of apoptosis (Figure 10B). The colony-forming 
assay also revealed that PD146176 significantly inhibited the abil-
ity of CML CD34+ cells to form progenitor colonies, with a lesser 
inhibitory effect on normal human CD34+ cells (Figure 10C). 
PD146176 in combination with imatinib or nilotinib did not fur-
ther inhibit the colony-forming ability of the cells within 24 hours 
of PD146176 treatment, whereas at 72 hours, PD146176 in combi-
nation with nilotinib more significantly inhibited colony formation 
than did PD146176 alone (Figure 10C). To further test the effect 
of PD146176 on human CML stem cells, CD34+CD38–CD90+ 
CML cells were sorted and treated with PD146176. We found that 
HL60. Although PD146176 inhibited the proliferation of HL60 
cells, its effect of on HL60 (Supplemental Figure 8) was smaller 
than on K562 cells (Figure 9A). In addition, PD146176 induced 
apoptosis of K562 cells (Figure 9B). To determine the signaling 
pathways involved in the apoptosis of K562 cells, we analyzed 
protein lysates of K562 cells treated with PD146176 for expres-
sion of a group of signaling molecules that have been shown to 
be involved in the regulation of CSC functions (11, 27, 38–42). 
We found that PD146176 markedly induced expression of PTEN, 
ICSBP, and caspase 9 and reduced the expression of β-catenin, 
PI3K, and AKT (Figure 9C). PD146176 did not significantly alter 
the expression of BCL2 or BAX (Figure 9C). To more definitively 
demonstrate that inhibition of Alox15 function inhibits prolifer-
ation of human leukemia cells, we conducted an Alox15 shRNA 
knockdown experiment using lentivirus. We found that Alox15 
knockdown led to growth inhibition (Figure 9D) and apoptosis 
induction (Figure 9E) of BV-173 cells.
Next, we tested whether inhibition of Alox15 function by 
PD146176 suppresses human CD34+ CML cells. Purified PB CML 
Figure 8. Functional relationship between Alox15 and SELP in HSCs. (A) Colony-forming ability of WT, Alox15–/–, Selp–/–, and Alox15–/– Selp–/– CML cells. 
BM cells were collected from CML mice on day 14 after BM transplantation (BMT) and plated into stem cell methocult media. Colonies were counted 
after 7 days. Results represent the mean ± SEM. (B) Apoptotic analysis of BM cells from WT, Alox15–/–, and Alox15–/– Selp–/– mice. Results represent the 
mean ± SD. (C and D) Overexpression of Selp inhibits the repopulating ability of HSCs. WT BM cells were transduced with GFP retrovirus or MSCV-Selp 
retrovirus, followed by transplantation into recipient mice. The percentage of GFP+ blood cells and GFP+Lin–c-Kit+Sca-1+ cells was determined at day 120 
after transplantation. A nontransduced control was included to rule out any possible effects of retroviral transduction on the FACS features of the cells. 
(E) Gene expression profiles of WT and Selp–/– HSCs were compared by DNA microarray assay. A group of cell growth–related genes is shown. Results 
represent the mean ± SD. **P < 0.01.
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or in combination with imatinib or nilotinib dramatically inhibited 
proliferation, as shown by the fewer number of cell divisions com-
pleted in the presence of the drug. Overall recovery of CD34+ CML 
cells across all cell divisions, including the CFSEmax undivided cell 
population, was clearly reduced by PD146176 (Figure 11D). These 
results demonstrate that Alox15 is a potential target gene for the 
treatment of human CML.
Discussion
The essential role of the Alox15 gene in regulating the function of 
LSCs in CML identifies Alox15 as a novel target gene in LSCs. It 
is striking that removal of a single gene or inhibition of its func-
tion alone causes a depletion of LSCs in CML mice and abolishes 
CML development. In agreement with our previously proposed 
hypothesis derived from the study of the specific role of Alox5 in 
functional regulation of LSCs (19), our results again support the 
PD146176 had a significant effect on CML stem cell elimination 
after 24 hours of drug treatment compared with that observed in 
the untreated control (P < 0.05), whereas nilotinib had very little 
to no effect on this primitive cell population. The killing effect of 
PD14176 on CML stem cells was not enhanced by nilotinib (Fig-
ure 11A). In the highly stringent in vitro LT culture–initiating cell 
(LTC-IC) assay, purified CML CD34+CD38–CD90+ cells were 
treated with the drug arms as indicated (Figure 11A) for 24 hours 
and further used to perform the LTC-IC assay. Treatment with 
PD146176 resulted in a significant (P < 0.05) decrease in CML 
stem cells in contrast to treatment with nilotinib (Figure 11B) 
and in increased apoptosis of these cells (Figure 11C). To further 
confirm the inhibitory effect of PD146176 on the proliferation of 
human CML stem cells, we labeled CD34+ CML cells with CFSE to 
track cell divisions and treated them with PD146176 (2 μM), with 
or without imatinib (0.5 μM) or nilotinib (0.5 μM). PD146176 alone 
Figure 9. Inhibition of Alox15 function induces apoptosis of human CML cell lines. (A) PD146176 inhibited proliferation of K562 cells. K562 cells were 
treated with DMSO or PD146176 (5, 10, 15, 20, and 50 μM) for 48 or 96 hours, and live cells were counted. Results represent the mean ± SD. (B) PD146176 
induced apoptosis of K562 cells. K562 cells were treated with DMSO or PD146176 (20 μM and 50 μM) for 48 hours. Apoptotic cells (annexin V+7AAD+) were 
analyzed by FACS. Results represent the mean ± SD. (C) Signaling pathways affected by PD146176. K562 cells were treated with PD146176 for 48 hours, 
and protein lysates were analyzed by Western blotting. PD146176 induced expression of PTEN, ICSBP, and caspase 9 and reduced expression of β-catenin, 
PI3K, and AKT, but did not significantly alter expression of BCL2 or BAX. (D) Alox15 knockdown caused growth inhibition of leukemia cells. BV-173 cells 
were transduced with scramble or Alox15-knockdown shRNA (shAlox15), and the transduced cells were selected with puromycin for 48 hours, followed 
by culturing the cells (2 × 106 cells per well in a 6-well plate) for 48 hours. At the end of the culture, protein lysates were analyzed by Western blotting for 
Alox15 expression, and viable cells were counted. Results represent the mean ± SD. (E) Alox15 knockdown induced apoptosis of leukemia cells. BV-173 cells 
were transduced with Alox15-knockdown shRNA (shAlox15), and the transduced cells were selected with puromycin for 48 hours, followed by culturing the 
cells for 48 hours. At the end of the culture, cellular apoptosis was assessed by FACS analysis of annexin V+7AAD+ cells. *P < 0.05; **P < 0.01.
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that of WT BM cells. Together, these results suggest that the MPD 
phenotype in Alox15–/– mice is likely a compensatory response to 
the reduced number of HSCs in the BM of Alox15–/– mice, which 
is consistent with our observation of more cycling myeloid cells in 
the spleen and upregulation of BCL2 in Alox15–/– mice (32). By con-
trast, we show that in K562 cells, inhibition of Alox15 function by 
PD146176 markedly induced expression of PTEN, ICSBP, and cas-
pase 9 and reduced the expression of β-catenin, PI3K, and AKT, 
with no significant effects on BCL2 or BAX. We believe that the 
different interpretations of similar results from the previous study 
(32) and our current study explain the conflicting role of Alox15.
The mechanism for the functional regulation of LSCs by 
Alox15 remains largely unknown, and we show that inhibition of 
Alox15 function by PD146176 alters β-catenin, PI3K, AKT, PTEN, 
and ICSBP levels in K562 cells. We and others have recently shown 
that β-catenin plays a critical role in CML LSCs (11, 27) and that 
PTEN is a tumor suppressor in LSCs in CML (42). Thus, the regu-
lation of these LSC-related genes by Alox15 indicates its role in the 
development of BCR-ABL–induced CML. Because Alox5 also reg-
ulates the expression of β-catenin in LSCs (19), Alox5 and Alox15 
could be functionally linked. However, we observed that Alox5 did 
not rescue the defective CML phenotype caused by Alox15 defi-
ciency, suggesting that these 2 genes are independently involved 
in the regulation of LSCs in CML. As with Alox5, the expression of 
Alox15 is upregulated by BCR-ABL and is not altered by imatinib, 
which may partially explain the insensitivity of LSCs to imatinib in 
principle that targeting CSCs or cancer-initiating cells provides 
a curative therapeutic strategy for cancer treatment. In stem cell 
regulation, Alox15 is different from Alox5 in that it also regulates 
the function of normal HSCs. However, Alox15 has a much more 
profound effect on LSCs than on HSCs, providing a therapeutic 
window for eradicating LSCs through targeting Alox15. Although 
we observed a strong inhibitory effect of PD146176 on CD34+ 
human CML cells, future clinical trials will be required to validate 
whether Alox15 is a useful target gene in CML therapy.
The requirement of Alox15 for LSC survival and CML devel-
opment in mice indicates that Alox15 plays a stimulatory role in 
CML. This conclusion conflicts with a previous study showing that 
Alox15 plays a suppressive role in a myeloproliferative disorder 
(MPD) (32). In that study, older Alox15–/– mice (>12 months of age) 
were shown to develop an MPD with an increase in Mac-1+ cells in 
PB and BM, and the mice also developed splenomegaly. In agree-
ment with that study, we show an increase in the percentages of 
CMPs, GMPs, and MEPs in BM and of Gr-1+ and Mac-1+ cells in PB. 
However, we found that the total numbers of HSCs were reduced 
in Alox15–/– mice, suggesting that Alox15 is required for the survival 
and self-renewal of HSCs. In addition, there were more HSCs in 
the S + G2/M phase of the cell cycle in Alox15–/– mice than in WT 
mice, showing that there were more proliferating HSCs in Alox15–/– 
mice, although the total number of HSCs was significantly lower 
in these mice. Furthermore, we found that the engraftment abil-
ity of Alox15–/– BM cells in lethally irradiated mice was lower than 
Figure 10. Inhibition of Alox15 function suppresses primary human CML cells. (A) CML CD34+ cells were treated with PD146176 for 24 or 72 hours. Cells 
were counted using the trypan blue exclusion assay (top), and apoptosis was assessed (annexin V+7AAD+) by FACS (bottom). (B) CML CD34+ cells were 
treated with PD146176, imatinib, or nilotinib alone or in combination for 24 hours (top) or 72 hours (bottom). The percentage of viable and apoptotic 
(annexin V+7AAD+) cells was analyzed. Results represent the mean ± SEM. (C) CML or normal CD34+ cells were treated with PD146176, imatinib, or nilotinib 
alone or in combination for 24 hours (top) or 72 hours (bottom) and replated for the CFC assay. Results represent the mean ± SEM. *P < 0.05.
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inhibiting Alox15 function indicates the importance of the Alox15 
pathway in regulating LSC function, and an in-depth study of this 
Alox15 network is critical to fully understanding the mechanisms 
for survival and self-renewal of LSCs. Our identification of SELP 
as a key downstream mediator of Alox15 provides the first clue to 
further dissecting the Alox15 pathway. Our previous work showed 
that loss of SELP accelerates BCR-ABL–induced CML in mice 
(36) and that SELP suppresses the functions of HSCs and LSCs 
(37), suggesting that Selp plays a suppressive role in hematopoie-
sis and CML development. Furthermore, we showed that SELP 
expression was upregulated in the absence of Alox15 and that loss 
of Selp rescued the defective CML phenotype in mice receiving 
BCR-ABL–transduced Alox15–/– BM cells, whereas overexpression 
of Alox15 diminished the function of HSCs. These results support 
the suppressive role of Selp in the functional regulation of LSCs. 
The regulatory role of Alox15 in LSCs appears to be cell autono-
mous, since the recipient mice in our leukemogenesis assay were 
WT mice. Because Alox15 plays a critical role in regulating LSC 
function and CML development, a complete understanding of 
the Alox15 pathway will help in the development of new thera-
peutic strategies for curing CML. We show that Alox15 function 
involves several important pathways such as PTEN, PI3K/AKT, 
and ICSBP, which play critical roles in cancer development. Thus, 
inhibition of Alox15 function may be beneficial in the treatment of 
other types of malignant diseases.
CML mice (26). It is reasonable to believe that Alox15 and Alox5 are 
key members of the molecular pathway critical for LSC function. 
It is hoped that targeting both Alox15 and Alox5 in combination 
with a BCR-ABL tyrosine kinase inhibitor or a BCR-ABL inhibitor 
that eliminates BCR-ABL protein, such as a heat shock protein 
90 inhibitor (34), would lead to a more complete control of CML. 
Besides regulating the same signaling molecules, such as β-catenin 
and PI3K (43), Alox15 and Alox5 appear to use distinct pathways 
to function in LSCs. These differences partially explain why both 
Alox5 and Alox15 regulate LSCs but are not functionally linked in 
signaling. Mechanistically, lipid metabolites produced by Alox15 or 
Alox5 could mediate their regulation of LSC function. However, we 
have observed that expression of β-catenin, PTEN, and ICSBP is 
regulated by Alox15 or Alox5 (19), and no published work has indi-
cated that the lipid metabolites produced by Alox15 or Alox5 affect 
the expression of these genes. It is possible that Alox15 and Alox5 
regulate LSC function through novel but distinct mechanisms 
independently of production of their lipid metabolites.
The findings in this study are the first to our knowledge to 
demonstrate that Alox15 plays an essential role in the functional 
regulation of LSCs in CML mice and in human CD34+ CML cells, 
providing a novel strategy for targeting CML in patients. Human 
CML microarray studies have shown that Alox15 is differentially 
expressed in CD34+ CML cells (44), suggesting a role of Alox15 in 
human CML. In addition, eradication of LSCs in CML mice by 
Figure 11. Inhibition of Alox15 function suppresses human CML stem cells. (A) CML stem cells (CD34+CD38–CD90+) sorted by FACS were treated with 
PD146176 or nilotinib or both for 24 hours. The number of treated and untreated CML stem cells was compared. Results represent the mean ± SEM.  
(B) CML stem cells were treated with PD146176 or nilotinib or both for 24 hours and plated on irradiated murine stromal cells for colony formation in the 
in vitro LTC-IC assay. Results represent the mean ± SEM. (C) CML stem cells were treated with PD146176 or nilotinib or both for 24 hours. Apoptotic cells 
(annexin V+DAPI+) were assessed by FACS. Results represent the mean ± SEM. (D) CML CD34+ cells from 3 patients were labeled with CFSE and then treated 
with PD146176 (2 μM) with or without imatinib (0.5 μM) or nilotinib (0.5 μM) for 6 days. The treated CD34+ CML cells were analyzed by FACS.  *P < 0.05.
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nologies), SCF, insulin-like growth factor-2, thrombopoietin, heparin, 
and α-fibroblast growth factor as described previously (34).
Homing experiment. The ability of WT and Alox15-deficient BM cells 
to home the bones of recipients was compared. A GFP strain was used 
as a WT control mouse, in which all blood cell lineages express GFP. 
GFP and Alox15–/– mice are positive for CD45.2. BM cells from the GFP 
and Alox15–/– mice were 1:1 mixed and then injected into CD45.1 mice. 
The percentages of CD45.2+GFP+ (WT) and CD45.2+GFP– (Alox15- 
deficient) cells in the PB of CD45.1 recipient mice were compared.
DNA microarray. BM cells from WT, Alox15–/–, or Selp–/– mice were 
isolated and subsequently FACS sorted for HSCs (Lin–c-Kit+Sca-1+). 
Total RNA was isolated from HSCs, and DNA microarray analysis 
was further carried out using Affymetrix chips. The DNA microarray 
results were deposited in the Gene Expression Omnibus database 
(GEO GSE29348 and GSE57459).
Lentiviral shRNA knockdown of Alox15 expression. BV-173 cells 
(3 × 106) were mixed with 0.5 ml Alox15 shRNA lentivirus in 6-well 
plates and spun at 1,900 g for 1.5 hours at 37°C in the presence of 
polybrene (10 μg/ml). The medium was changed after 24 hours, and 
puromycin (2.5 μg/ml) was added for selection of the transduced cells.
Histology. The lungs from the placebo- or drug-treated mice were 
fixed in Bouin fixative (Fisher Scientific) for 24 hours at room temperature, 
followed by an overnight rinse in water. Sections (10-μm) were stained 
with H&E and observed using a model DMRE compound microscope 
(Leica). All sections were imaged with a 2.5 × PH1 objective (NPLan, NA 
0.25) and × 10 PH1 objective (NPLan, NA 0.40). All images were imported 
into MetaMorph software (Molecular Devices) as a series of tagged image 
files and then constructed in Adobe Photoshop CS4 (Adobe).
Patient samples. The CD34+ cell population was enriched using 
CliniMACS (Miltenyi Biotec) according to standard protocols, before 
storage in aliquots at –150°C. CML CD34+ samples (n = 4) were cultured 
in a humidified incubator at 37°C and 5% CO2 in serum-free medium 
(SFM) consisting of Iscove’s modified Dulbecco’s medium (Sigma- 
Aldrich) supplemented with serum substitute (BSA, insulin, and trans-
ferrin [BIT9500]; STEMCELL Technologies), 2 mM L-glutamine, 
105 units/ml penicillin, 100 mg/ml streptomycin, 0.1 mM 2-mercapto-
ethanol, and 0.8 μg/ml LDL (all from Sigma-Aldrich). SFM was 
supplemented with a growth factor cocktail of 0.20 ng/ml recom-
binant human (rh) SCF, 1 ng/ml rh IL-6, 0.20 ng/ml rh granulocyte- 
macrophage CSF (GM-CSF) (Chugai Pharma Europe), 0.05 ng/ml LIF, 
0.2 ng/ml MIPα (all from STEMCELL Technologies unless other-
wise indicated). “Normal CD34+” or non-CML samples (n = 2) were 
CD34+-enriched leukapheresis products maintained and used as 
described for CML CD34+ samples.
Cell counting and apoptosis assays. After retrieval from –150°C ali-
quots and an overnight incubation, cells were seeded in 24-well plates 
at 1 × 106 cells/ml before drug exposure. After treatment, the aliquots 
were removed and counted in duplicate by trypan blue (Sigma-Aldrich) 
exclusion. Apoptosis was quantified by phosphatidylserine external-
ization. Briefly, samples were stained with annexin V-FITC and 7AAD 
(Via-Probe solution; both from BD Biosciences) according to the manu-
facturer’s recommendations. FACSCalibur flow cytometry (BD Biosci-
ences) enabled the distinction of viable cells (annexin V-FITC–, 7AAD–) 
from those in apoptosis (annexin V-FITC+, 7AAD+). Unless otherwise 
indicated, all results are expressed as the mean ± SEM.
Mouse colony forming cell assay. To evaluate the effect of PD146176 
on CML progenitor cells, BCR-ABL–expressing cells from the BM of 
Methods
Mice. C57BL/6J-CD45.1, C57BL/6J-CD45.2, and homozygous Alox15-
knockout (Alox15–/–) and homozygous Selp-knockout (Selp–/–) mice on 
a  C57BL/6 background were obtained from The Jackson Laboratory. 
The Alox15–/– Selp–/– strain is viable and grows normally and was gener-
ated by crossing Alox15–/– mice with Selp–/– mice. Mice were maintained 
in a temperature- and humidity-controlled environment and given 
unrestricted access to a 6% chow diet and acidified water.
Cell lines. Human BCR-ABL–expressing K562, HL60, and BV-173 
leukemia cell lines were grown in RPMI 1640 medium containing 
10% FCS. 293T and NIH3T3 cell lines were grown in DMEM con-
taining 10% FCS.
FACS and identification of leukemia and normal hematopoietic cell 
lineages. Hematopoietic cells were collected from the BM and PB of the 
normal and diseased mice, and red blood cells were lysed with NH4Cl 
red blood cell lysis buffer (pH 7.4). The cells were washed with PBS and 
stained with B220-PE for B cells, Gr-1-APC for neutrophils, Mac-1-PE for 
macrophages, CD3E-APC for T cells, SELP-PE for Selp, and Sca-1-APC/
c-Kit-PE/CD34-Pacific blue for hematopoietic stem cells. After staining, 
the cells were washed once with PBS and subjected to FACS analysis.
BM transduction and transplantation. The retroviral vector MSCV-
IRES-GFP carrying p210 BCR-ABL cDNA was used to make high-titer, 
helper-free, replication-defective ecotropic virus stock by transient 
transfection of 293T cells using the kat system as previously described 
(45). The viral titers were evaluated by infecting 3T3 cells and analyz-
ing protein lysates by Western blotting for detection of BCR-ABL pro-
tein expression levels. The viruses were normalized to a similar titer 
prior to induction of CML in mice. Six- to 8-week-old WT C57BL/6, 
Alox15–/–, or Selp–/– mice were used for leukemogenesis experiments. 
Induction of CML was performed as previously described (34, 46). 
Briefly, to model CML, BM from 5-FU–treated (200 mg/kg) donor 
mice was transduced twice with BCR-ABL retrovirus by cosedimen-
tation in the presence of IL-3, IL-6, and stem cell factor (SCF). WT 
recipient mice received 1,100 cGy gamma irradiation (given by 2 split 
550-cGy doses), and 0.5 × 106 (CML) cells were transplanted into the 
recipient mice via tail vein injection. Each recipient mouse received 
5 × 105 BCR-ABL–transduced donor BM cells from WT, Alox15–/–, or 
Selp–/– mice. There were typically 10 mice in each cohort of CML mice; 
however, occasionally, a few mice died prematurely within 10 days 
after CML induction due to technical reasons. When this occurred, the 
dead mice were removed from the experiment.
Western blot analysis and antibodies. Antibodies against c-ABL, 
β-catenin, BCL-2, BAX, ICSBP, β-actin, and Alox15 were purchased 
from Santa Cruz Biotechnology Inc., and antibodies against P53, PTEN 
PI3K, AKT, and caspase 9 were purchased from Cell Signaling Tech-
nology. Protein lysates were prepared by lysing cells in RIPA buffer, and 
Western blot analysis was performed as previously described (47).
Real-time PCR. Total mRNA was extracted from LSCs isolated by 
FACS sorting. cDNA was synthesized using the Ovation-Pico (NuGEN) 
cDNA synthesis method. RT-PCR was performed to detect Alox15 
expression with the following primers: forward primer, CAGGGATCG-
GAGTACACGTT; reverse primer, GATTGTGCCATCCTTCCAGT. The 
Power SYBR Green PCR master mix was obtained from Applied Biosys-
tems. The number of copies of Alox15 mRNA relative to 1,000 copies of 
β-actin mRNA reflect the abundance of mRNA copies detected.
In vitro culture of LSCs. BM cells isolated from CML mice were cul-
tured in vitro in the presence of StemSpan SFEM (STEMCELL Tech-
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Statistics. Statistical analyses were performed using a 1-tailed Stu-
dent’s t test (*P < 0.05; **P < 0.01) and GraphPad Prism software, ver-
sion 5.01 for Windows (GraphPad Software). A P value less than 0.05 
was considered statistically significant.
Study approval. Mice were maintained and handled in accordance 
with the protocols and regulations approved by the IACUC of the Uni-
versity of Massachusetts Medical School. Patient samples consisted of 
leukapheresis products taken at the time of diagnosis of chronic-phase 
CML, and written informed consent was obtained in accordance with 
Declaration of Helsinki principles and with IRB approval from the 
National Health Service Greater Glasgow.
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CML mice were treated with PD146176 in vitro in a colony-forming 
assay; also, CML mice were treated with PD146176, and then BM cells 
were isolated for analysis in the colony-forming assay, which was car-
ried out as previously described (48).
Human colony-forming cell assay. Primary CML cells or non-CML 
CD34+ cells were treated for 24 or 72 hours with the indicated concen-
trations of PD146176, imatinib, or nilotinib, individually or in combi-
nation (Figure 10). Untreated and drug-treated cells and cells that had 
no prior culture or treatment (baseline) were seeded in methylcellulose 
medium (Methocult H4034; STEMCELL Technologies). The forma-
tion of colonies was assessed 14 days after plating 2,500 cells per plate.
Human CML stem cell assay. After purifying a primitive popula-
tion of LSCs (CD34+CD38– and CD90+) using sorting techniques, the 
CML cells were treated with PD146176, nilotinib, or both. LSCs were 
identified and quantitated by FACS. In the highly stringent in vitro 
LTC-IC assay, purified CML cells that expressed CD34+CD38– and 
CD90+ only were treated with the drug arms, as indicated (Figure 11), 
for 24 hours and were plated on irradiated murine stromal cells. After 
6 weeks, cells were harvested, counted, and inoculated into methyl-
cellulose media (Methocult H4435; STEMCELL Technologies). After 
2 weeks, colonies were counted, and a functional readout was obtained 
for quantitation of the most primitive cells.
Drug treatment. To model CML, BM from 5-FU–treated (200 
mg/kg) donor mice was transduced twice with BCR-ABL retrovirus 
by cosedimentation in the presence of IL-3, IL-6, and SCF. WT recip-
ient mice received 1,100 cGy gamma irradiation (administered by 2 
split 550-cGy doses), and 0.5 × 106 (CML) cells were transplanted into 
recipient mice via tail vein injection. After 8 days, CML mice with con-
firmed disease were randomly enrolled into the placebo or drug treat-
ment groups. PD146176 (Cayman Chemical) was dissolved in DMSO, 
cremophor EL, alcohol, and PBS. The drug was administered orally 
in a volume of less than 0.3 ml by gavage (100 mg/kg every day for 
PD146176) beginning 8 days after BM transplantation and continuing 
until the morbidity or death of the leukemic mice. The placebo con-
sisted of a solution containing DMSO, cremophor EL, alcohol, and PBS.
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